Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution

Adjuvant trastuzumab is currently an internationally standard for the treatment of localised breast cancer that over express HER2 with the most adverse effect being cardiotoxicity. We conducted this study to evaluate the cardiac safety of trastuzumab in clinical practice.

Bibliographic Details
Main Authors: Hamed Rasha Hamdy, Salim Khalid, Alzahrani Abdullah, Elsamany Shereef
Format: Article
Language:English
Published: Sciendo 2016-06-01
Series:Forum of Clinical Oncology
Subjects:
Online Access:https://doi.org/10.1515/fco-2016-0007
_version_ 1818191862274457600
author Hamed Rasha Hamdy
Salim Khalid
Alzahrani Abdullah
Elsamany Shereef
author_facet Hamed Rasha Hamdy
Salim Khalid
Alzahrani Abdullah
Elsamany Shereef
author_sort Hamed Rasha Hamdy
collection DOAJ
description Adjuvant trastuzumab is currently an internationally standard for the treatment of localised breast cancer that over express HER2 with the most adverse effect being cardiotoxicity. We conducted this study to evaluate the cardiac safety of trastuzumab in clinical practice.
first_indexed 2024-12-12T00:21:21Z
format Article
id doaj.art-0cb6c97c6923469aac094e5d8c895856
institution Directory Open Access Journal
issn 1792-362X
language English
last_indexed 2024-12-12T00:21:21Z
publishDate 2016-06-01
publisher Sciendo
record_format Article
series Forum of Clinical Oncology
spelling doaj.art-0cb6c97c6923469aac094e5d8c8958562022-12-22T00:44:43ZengSciendoForum of Clinical Oncology1792-362X2016-06-01721610.1515/fco-2016-0007fco-2016-0007Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institutionHamed Rasha Hamdy0Salim Khalid1Alzahrani Abdullah2Elsamany Shereef3Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt, Mansoura, EgyptCardiology, King Abdulla Medical City Makkah, Kingdom of Saudi Arabia Medical Oncology, Oncology Center of King Abdulla Medical City (KAMC), Makkah, Kingdom of Saudi Arabia Medical Oncology, Oncology Center of King Abdulla Medical City (KAMC), Makkah, Kingdom of Saudi ArabiaAdjuvant trastuzumab is currently an internationally standard for the treatment of localised breast cancer that over express HER2 with the most adverse effect being cardiotoxicity. We conducted this study to evaluate the cardiac safety of trastuzumab in clinical practice.https://doi.org/10.1515/fco-2016-0007cardiotoxicityadjuvant trastuzumabinbreast cancer
spellingShingle Hamed Rasha Hamdy
Salim Khalid
Alzahrani Abdullah
Elsamany Shereef
Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
Forum of Clinical Oncology
cardiotoxicity
adjuvant trastuzumabin
breast cancer
title Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
title_full Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
title_fullStr Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
title_full_unstemmed Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
title_short Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution
title_sort cardiotoxicity of the adjuvant trastuzumab in a saudi population clinical experience of a single institution
topic cardiotoxicity
adjuvant trastuzumabin
breast cancer
url https://doi.org/10.1515/fco-2016-0007
work_keys_str_mv AT hamedrashahamdy cardiotoxicityoftheadjuvanttrastuzumabinasaudipopulationclinicalexperienceofasingleinstitution
AT salimkhalid cardiotoxicityoftheadjuvanttrastuzumabinasaudipopulationclinicalexperienceofasingleinstitution
AT alzahraniabdullah cardiotoxicityoftheadjuvanttrastuzumabinasaudipopulationclinicalexperienceofasingleinstitution
AT elsamanyshereef cardiotoxicityoftheadjuvanttrastuzumabinasaudipopulationclinicalexperienceofasingleinstitution